製藥和生物技術交易中的特許權使用費率（2010-2025）

本報告廣泛涵蓋了製藥和生物技術行業，並提供了2010年至2025年交易的詳細數據，包括許可的技術、特許權使用費率、許可費和預付款。

目錄

摘要整理

第1章 簡介

• 什麼是版稅？
• 特許費率歷史記錄
• 製藥和生物技術特許權使用費
• 特許權使用費與收益分成
• 報告概述

第2章 醫藥品·生物科技的特許權使用費費率概要

• 特許權使用費率趨勢 (2010-2025)
• 如何計算收入分成
• 近期文獻回顧
• 未來特許權使用費率

第3章 醫藥品·生物科技交易的特許權使用費條款

• 合作夥伴契約結構
• 典型性的特許權使用費條款結構
• 特許權使用費條款範例
  • 案例研究1
  • 案例研究2
  • 案例研究3
  • 案例研究4

第4章 積極地明確指示特許權使用費費率的企業

• 最願意揭露特許費率的公司

第5章 特許權使用費費率契約名錄

• 查看貿易協定中的特許費率，以獲得更深入的了解
• 貿易目錄
• 交易目錄 - 特許權使用費率（按交易）- 公司（A-Z）
• 交易目錄 - 交易中的特許權使用費率 - 按治療領域
• 交易目錄 - 協議簽訂時按開發階段劃分的交易特許權使用費率
• 交易目錄 - 交易中的特許權使用費率 - 按技術類型
• 特許權使用費率參考
• 特許費率交易協議範例
• 關於Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Current Partnering的近幾年的報告標題

Royalty Rates in Pharmaceutical and Biotechnology Deals is your one-stop source for providing real-deal information on hundreds of transactions, including the technology licensed, royalty rates, license fees, upfront and milestone payments.

This report provides details of the latest partnering deals which disclose a royalty rate announced in the pharmaceutical, biotechnology and diagnostic sectors. The report provides details of 700+ partnering deals disclosing royalty rates from 2010 to 2025.

The report provides an overview of how and why companies enter partnering deals where a royalty is payable upon commercialization of the compound or technology.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of 700+ partnering deals announced since 2010 where a quantitative royalty rate has been disclosed, as recorded in the Current Agreements deals and alliances database. Each deal record and royalty disclosure is available in further detail via a link to online copy of the deal including actual contract document, where available, as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of royalty rate trends in pharma and biotech since 2010. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in royalty rates in the pharma and biotech sectors since 2010.

Chapter 3 provides a more detailed insight into the structure of a royalty rate clause and how it fits with the other financial terms of the partnering deal.

Chapter 4 provides an insight into companies active in disclosing royalty rates as well as those deals attracting the highest royalty rates.

Chapter 5 provides comprehensive and detailed access to deals which disclose a royalty rate since 2010 where a contract document is available. Contract documents provide an in-depth insight into the actual deal terms agreed between the parties with respect to the royalty rate.

In addition the report includes a comprehensive deal directory listing of all deals where a royalty rate has been disclosed announced since 2010. Each listing is organized as a directory by company A-Z, stage of development at signing, therapeutic area, and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends in royalty rates in pharma and biotech deal making since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty rates in the pharma and biotech sector.

Key benefits

Royalty Rates in Pharmaceutical and Biotechnology Deals provides the following benefits:

• Understand royalty rate trends since 2010
• Analysis of the structure of royalty clauses with real life case studies
• Browse collaboration and licensing deals which reveal a royalty rate
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Royalty Rates in Pharmaceutical and Biotechnology Deals is intended to provide the reader with an in-depth understanding of the royalty rate trends and structure of deals entered into by leading life science companies worldwide.

Royalty Rates in Pharmaceutical and Biotechnology Deals includes:

• Trends in royalty rates in the biopharma industry since 2010
• Analysis of royalty rate clause structure
• Case studies of real-life licensing deals which disclose royalty rates
• Comprehensive listing of licensing deals which disclose royalty rates since 2010
• Access to licensing contract documents which disclose royalty rates
• The leading licensing deals by royalty rate value since 2010
• Most active royalty rate disclosures since 2010

In Royalty Rates in Pharmaceutical and Biotechnology Deals available deals and contracts are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
• The Royalty Rates in Pharmaceutical and Biotechnology Deals report provides comprehensive access to available contract documents for licensing deals.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise royalty rates granted?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

• 1.1. What are royalties?
• 1.2. History of royalty rates
• 1.3. Royalties in pharmaceuticals and biotechnology
• 1.4. Royalties versus revenue share
• 1.5. Overview of the report

Chapter 2 - An overview of pharmaceutical and biotechnology royalty rates

• 2.1. Trends in royalty rates 2010 - 2025
• 2.2. How do revenue shares figure?
• 2.3. A review of recent literature
• 2.4. Royalty rates in the future

Chapter 3 - The royalty clause in pharmaceutical and biotechnology deals

• 3.1. Partnering agreement structure
• 3.2. Structure of a typical royalty clause
• 3.3. Example royalty clauses
  • 3.3.1. Case study 1
  • 3.3.2. Case study 2
  • 3.3.3. Case study 3
  • 3.3.4. Case study 4

Chapter 4 - Companies actively disclosing royalty rates

• 4.1. Most active companies in disclosing royalty rates

Chapter 5 - Royalty rate contract directory

• Explore royalty rates within the deal contract document to gain greater insight
• Deal Directory
• Deal Directory - Royalty rates in deals - by company A-Z
• Deal Directory - Royalty rates in deals - by therapy area
• Deal Directory - Royalty rates in deals - by stage of development at signing
• Deal Directory - Royalty rates in deals - by technology type
• Royalty rate references
• Example royalty rate deal contract document
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Trends in pharma and biotech royalty rates, 2010 - 2025
• Figure 2: Components of the partnering deal structure
• Figure 3: Components of the partnering royalty clause
• Figure 4: Most active companies disclosing royalty rate 2010 - 2025
• Figure 5: Licensing agreement for rhAAT - rEVO Biologics, LFB Biotechnologies